XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

NCT05494060 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators